Article Text

Download PDFPDF
Prognostic value of long non-coding RNA 01296 expression in human solid malignant tumours: a meta-analysis
  1. Chen Dai1,
  2. Chenguang Dai2,
  3. Hao Ni3,
  4. Zhihua Xu1
  1. 1General Surgery, First Affiliated Hospital of Soochow University, Suzhou, China
  2. 2Gastroenterology, First Affiliated Hospital of Soochow University, Suzhou, China
  3. 3Pathology, First Affiliated Hospital of Soochow University, Suzhou, China
  1. Correspondence to Dr Zhihua Xu, General Surgery, First Affiliated Hospital of Soochow University, Suzhou 215006, China; dr_zhihuaxu{at}; Dr Hao Ni, Pathology, First Affiliated Hospital of Soochow University, Suzhou 215006, China; nihao911211{at}


Long intergenic non-coding RNA 01296 (LINC01296) has been reported to play an important role in many human malignancies, but a consistent perspective has not been established now. To explore the prognostic value of LINC01296 in different types of human solid malignant tumours, we performed this meta-analysis.An electronic search of PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, Cochrane Library, Chinese Biological Medical Literature database and WanFang database was applied to select eligible literatures. Pooled ORs or HRs with their 95% CIs were calculated to estimate the effects.A total of 559 patients from nine eligible studies were enrolled in this meta-analysis. The results revealed that high LINC01296 expression was significantly related to larger tumour size (OR 3.42, 95% CI 2.08 to 5.63), lymph node metastasis (OR 3.03, 95% CI 2.01 to 4.57) and advanced tumor-node-metastasis (TNM) stage (OR 4.41, 95% CI 2.65 to 7.34). Moreover, we found that elevated LINC01296 expression predicted a poor outcome for overall survival (HR 1.78, 95% CI 1.48 to 2.14) and recurrence-free survival (HR 4.00, 95% CI 1.04 to 15.67).High expression levels of LINC01296 were associated with unfavourable clinical outcomes of patients with cancer. Our results indicated that LINC01296 could serve as a prognostic predictor in human solid malignant tumours.

  • LINC01296
  • human solid malignant tumor
  • clinicopathological feature
  • prognosis
  • meta-analysis
View Full Text

Statistics from


  • CD and CD are joint first authors.

  • Contributors ChenD and ChengD drafted the work and assessed the included studies. The data were extracted from the included studies by two reviewers (ZX and HN). All authors did the final approval of the version to be published and agreed to be accountable for all aspects of the work.

  • Funding This work was supported by the foundation of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (18KJB320018).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.